Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 252 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsed Pediatric ALL Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Interventions
Lurbinectedin
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 21, 2026, 11:54 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
Interventions
FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Pheresis, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 6 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
131I-MIBG
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced May 21, 2026, 11:54 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Interventions
67Cu-SARTATE, 64Cu-SARTATE
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • St Louis, Missouri • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
Interventions
TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg, TB-403 175mg/kg
Drug
Lead sponsor
Oncurious NV
Industry
Eligibility
6 Months to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced May 21, 2026, 11:54 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 11:54 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
Interventions
Enoblituzumab
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
1 Year to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced May 21, 2026, 11:54 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Day to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Asthma
Interventions
Nebulized Budesonide, Usual care (albuterol with or without oral steroid)
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
1 Year to 8 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Bellevue, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced May 21, 2026, 11:54 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
Interventions
ET140203 T Cells
Drug
Lead sponsor
Eureka Therapeutics Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Everolimus, Prednisone, Vincristine, PEG-Asparaginase, Doxorubicin, Dexrazoxane
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Months to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced May 21, 2026, 11:54 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Refractory Acute Leukemia, Relapsed Acute Leukemia, Undifferentiated Leukemia, Bi-Phenotypic Leukemia
Interventions
Venetoclax, Hyper-CVAD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 11:54 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced May 21, 2026, 11:54 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroblastoma
Interventions
Fludarabine, Cyclophosphamide, Natural Killer Cell Infusion, Mesna, Interleukin-2
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced May 21, 2026, 11:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Synovial Sarcoma
Interventions
Ramucirumab, Gemcitabine, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
74
States / cities
Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
CTL019
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced May 21, 2026, 11:54 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Biological
Lead sponsor
Amgen Research (Munich) GmbH
Industry
Eligibility
Up to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced May 21, 2026, 11:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced May 21, 2026, 11:54 PM EDT